Complications of lung cancer treatment

Seminars in Respiratory and Critical Care Medicine

Volumn 29, Issue 3, 2008, Pages 302-317

  Spiro, Stephen G ^a   Douse, Jonathan ^a   Read, Catherine ^a   Janes, Sam ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Complications; Palliative care; Radiation therapy; Surgery

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CODEINE; CORTICOSTEROID; CYTOKINE; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MITOMYCIN; MORPHINE; NAVELBINE; OPIATE; PACLITAXEL; PREDNISOLONE; STEROID; VINCA ALKALOID;

ACUTE LUNG INJURY; ADJUVANT CHEMOTHERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ASPIRATION PNEUMONIA; ATELECTASIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRONCHOPLEURAL FISTULA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EMPYEMA; ESOPHAGITIS; FEAR; FIBROSIS; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HOSPITAL INFECTION; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; HYPOXIA; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG INFECTION; LUNG INFILTRATE; LUNG RESECTION; LUNG TOXICITY; MORBIDITY; MYELITIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NERVE INJURY; NEUROTOXICITY; NEUTROPENIA; PAIN; PALLIATIVE THERAPY; PERICARDIAL DISEASE; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; RADIATION PNEUMONIA; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SECOND CANCER; SEDATION; SIDE EFFECT; SKIN TOXICITY; SPINAL CORD DISEASE; STROKE; SURGICAL MORTALITY; THORACOTOMY; THROMBOCYTOPENIA; TUMOR GROWTH; URTICARIA; VOMITING; WOUND INFECTION; XEROSTOMIA;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG; LUNG NEOPLASMS; PALLIATIVE CARE; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RADIATION INJURIES; RESPIRATORY TRACT FISTULA; RESPIRATORY TRACT INFECTIONS;

EID: 44349193939     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1076750     Document Type: Review

References (139)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics review 1975-2000. http://seer.cancer.gov/csr/1975_2000
2. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997;33:2313-2314
3. Spiro SG, Gower NH, Evans MT, et al. Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. Thorax 2000;55:463-465
4. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005;23:9113-9119
5. Martin-Ucar AE, Waller DA, Atkins JL, et al. The beneficial effects of specialist thoracic surgery on the resection rate for non-small cell lung cancer. Lung Cancer 2004;46:227-232
6. Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major non-cardiac surgery. Ann Surg 2000;232:242-250
7. Arozullah AM, Khuri SF, Henderson WG, Daley J. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major non-cardiac surgery. Ann Intern Med 2001;135:847-857
8. Rostad H, Strand T-E, Naalsuund A, Talleraas O, Norstein J. Lung cancer surgery: the first 60 days: a population-based study. Eur J Cardiothorac Surg 2006;29:824-828
9. Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001;121:1076-1082
10. Harpole DH, Liptay MJ, DeCamp MM, et al. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg 1996;61:977-982
11. Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg 1995;109:275-283
12. Yildizeli B, Fadel E, Mussot S, et al. Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;31:95-102
13. Van Schil P, Van Meerbeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 Trial. Eur Resp J 2005;26:192-197
14. Gilligan D, Nicholson M, Smith I, et al. Preoperative chemotherapy in patients with respectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-1937
15. De Pauw R, van Meerbeeck JP. Neoadjuvant chemotherapy in the treatment of non small cell lung cancer. Curr Opin Oncol 2007;19:92-97
16. Leo F, Solli P, Veronesi G, Radice D, et al. Does chemotherapy increase the risk of respiratory complications after pneumonectomy? J Thorac Cardiovasc Surg 2006;132:519-523
17. Venuta F, Anile M, Diso D, Ibrahim M. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 2007;31:714-717
18. Mansour Z, Kochetkova EA, Ducrocq X, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy!. Eur J Cardiothorac Surg 2007;31:181-185
19. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909
20. Arriagada R, Bergman B, Dumant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non small-cell lung cancer. N Engl J Med 2004;350:351-360
21. Waller D, Peake MD, Stephens RJ. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182
22. Belda J, Calvacanti M, Ferrer M, et al. Bronchial colonisation and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 2005;Sp; 128(3):1571-1579
23. Cabello H, Torres A, Celis R, et al. Bacterial colonisation of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997;10:1137-1144
24. Ioanas M, Angrill J, Baldo X, et al. Bronchial bacterial colonisation in patients with respectable lung cancer. Eur Respir J 2002;19:326-332
25. Belda J, Cavalcanti M, Ferrer M, et al. Bronchial colonisation and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 2005;128:1571-1579
26. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease(GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276
27. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-1022
28. Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg 2006;81:1830-1838
29. Volpino P, Cangemi R, Fiori E, et al. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer. J Cardiovasc Surg (Torino) 2007;48:375-383
30. Sonobe M, Nakagawa M, Ichinose M, et al. Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 2000;18:519-523
31. Deschamps C, Bernard A, Nichols FC, et al. Empyema and bronchopleural fistula after pneumonectomy: factors affecting incidence. Ann Thorac Surg 2001;72:243-247
32. Myrdal G, Valtysdottir M, Lambe M, Stahle E. Quality of life following lung cancer surgery. Thorax 2003;58:194-197
33. Win T, Sharples L, Wells FC, Ritchie AJ, Munday H, Laroche CM. Effect of lung cancer surgery on quality of life. Thorax 2005;60:234-238
34. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of life of long-term survivors of non-small cell ling cancer. J Clin Oncol 2002;20:2920-2929
35. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973-985
36. Kong FM, Ten Haken R, Eisbruch A, Lawrence TS. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005;32(2, Suppl 3):S42-S54
37. Lopez Rodriguez M, Cerezo Padellano L. Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol 2007;9:506-512
38. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 2007;175:547-553; Epub 2006 Dec 7
39. Van der Kogel AJ, Ang KK. Complications related to radiotherapy. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press; 1995:2295-2306
40. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. Chest 1997;111:1061-1076
41. Davis SD, Yankelevitz DF, Henschke CI. Radiation effects on the lung: clinical features, pathology, and imaging findings. AJR Am J Roentgenol 1992;159:1157-1164
42. Van Houtte P, Mornex P. Radiotherapy of non-small-cell and small-cell and SCLC. In: Spiro SG, ed. Carcinoma of the Lung. European Respiratory Monograph, Vol 1. Leeds, UK: Maney Publishers; 1995:241-268
43. Bate D, Guttemann RJ. Changes in the lung and pleura following 2-million volt therapy for carcinoma of the breast. Radiology 1957;69:372-382
44. Ross WM. Radiotherapeutic and radiological aspects of radiation fibrosis of the lungs. Thorax 1956;11:241-246
45. Libshitz HI, Southard ME. Complications of radiation therapy: the thorax. Semin Roentgenol 1974;9:41-49
46. Roswit B, White DC. Severe radiation injuries of the lung. AJR Am J Roentgenol 1977;129:127-136
47. Bachman AL, Macken K. Pleural effusions following supervoltage radiation for breast carcinoma. Radiology 1959;72:699-709
48. Libshitz HI, Shuman LS. Radiation-induced pulmonary change: CT findings. J Comput Assist Tomogr 1984;8:15-19
49. Glazer HS, Lee JKT, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985;156:721-726
50. Kataoka M, Kawamura M, Itho H, et al. Ga-67 citrate scintigraphy for the early detection of radiation pneumonitis. Clin Nucl Med 1992;17:27-31
51. Watchie J, Coleman CN, Raffin TA, et al. Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1987;13:517-524
52. Lokich JJ, Brass H, Eberly FE, et al. The pulmonary effect of mantle irradiation in patients with Hodgkin's disease. Radiology 1973;108:397-402
53. Uitterhoeve AL, Koolen MG, van Os RM, et al. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy, treatments of choice in patients with non-small cell lung cancer. Radiat Oncol 2007;2:27
54. Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003;40:79-84
55. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004;44:363-368
56. Nagata Y, Matsuo Y, Takayama K, et al. Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol 2007;12:3-7; Epub 2007 Feb 25
57. Li X, Zhang P, Mah D, Gewanter R, Kutcher G. Novel lung IMRT planning algorithms with nonuniform dose delivery strategy to account for respiratory motion. Med Phys 2006;33:3390-3398
58. Liu R, Buatti JM, Howes TL, Dill J, Modrick JM, Meeks SL. Optimal number of beams for stereotactic body radiotherapy of lung and liver lesions. Int J Radiat Oncol Biol Phys 2006;66:906-912; Epub 2006 Aug 14
59. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective srudy. Radiother Oncol 2003;67:275-283
60. Jenkins P, D'Amico K, Benstead K, Elyan S. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy(CHART). Int J Radiat Oncol Biol Phyl 2003;56:360-366
61. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformai radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:329-339
62. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899-908
63. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977;86:81-92
64. Wang JY, Chen KY, Wang J, et al. Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002;54:735-741
65. Rubin O, Casarett GW. Clinical Radiation Pathology. Philadelphia: WB Saunders; 1968:423-470
66. Bennett DE, Million RR, Ackerman LV. Bilateral radiation pneumonitis: a complication of the radiotherapy of bronchogenic carcinoma. Cancer 1969;23:1001-1018
67. Coggle JE, Lambert BE, Moores SR. Radiation effects in the lung. Environ Health Perspect 1986;70:261-291
68. Crestani B, Valeyre D, Roden S, et al. Bronchiolitis obliterans organising pneumonia syndrome primed by radiation therapy to the breast. Am J Respir Crit Care Med 1998;158:1929-1935
69. Martin C, Romero S, Sanchez-Paya J, et al. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J 1999;13:727-732
70. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730
71. Johnson BE, Cortazar P, Chute JP. Second lung cancers in patients successfully treated for lung cancer. Semin Oncol 1997;24:492-499
72. Van Bodegom PC, Wagenaar SS, Corrin B, et al. Second primary lung cancer: Importance of long term follow up. Thorax 1989;44:788-793
73. Sugimura H, Watanabe S, Tsugane S, et al. Case-control study on histologically determined multiple primary lung cancer. J Natl Cancer Inst 1987;79:435-441
74. Mathisen DJ, Jensik RJ, Faber LP, Kittle CF. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg 1984;88:502-510
75. Deschamps C, Pairolero PC, Trastek VF, Payne WS. Multiple primary lung cancers: results of surgical treatment. Ann Thorac Cardiovasc Surg 1990;99:769-777; discussion 777-778
76. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81
77. Kirova YM, Feuilhade F, Calitchi E, et al. Radiation-induced sarcoma after breast cancer: apropos of 8 cases and review of the literature. Cancer Radiother 1998;2:381-386
78. Van der Kogel AJ. Radiation response and tolerance of normal tissues. In: Steel GG, ed. Basic Clinical Radiobiology. London, UK: Arnold; 1997:30-39
79. Stewart JR, Fajardo LF. Radiation-induced heart disease: an update. Prog Cardiovasc Dis 1984;27:173-194
80. Schultz-Hector S. Heart. In: Scherer E, Streffer C, Trott KR, eds. Radiopathology of Organs and Tissues. Berlin: Springer-Verlag; 1991:347-368
81. Brosius FC, Waller BF, Roberts WL. Analysis of 16 young (aged 15-33 years) necropsy patients who received over 3500 rads to the heart. Am J Med 1981;70:519-530
82. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-263
83. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999;86:265-273
84. Van der Kogel AJ, Ang KK. Complications related to radiotherapy. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press; 1995:2295-2306
85. Macbeth FR, Wheldon TE, Girling DJ, et al. Radiation myelopathy: estimates of risk in 1048 patients in three randomised trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996;8:176-181
86. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194
87. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus best supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-836
88. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98
89. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomised study of the London Lung Cancer Group. J Clin Oncol 2005;23:142-153
90. Dimitroulis J, Stathopoulos GP. Evolution of non small cell lung cancer chemotherapy [review]. Oncol Rep 2005;13:923-930
91. Ruckdeschel JC, Finkelstein DM, Mason BA, et al. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985;3:72-79
92. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small cell lung cancer patients with ECOG performance status 2: results of an European Expert Panel. Ann Oncol 2004;15:419-426
93. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 2001;357:1478-1484
94. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomised trial. J Clin Oncol 2002;20:3578-3585
95. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomised trial. J Clin Oncol 2003;21:3207-3213
96. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2003;21:3025-3034
97. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-1907
98. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72
99. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-998
100. Morittu L, Earl HM, Souhami RL, et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 1989;59:801-804
101. Carnes P, White DA. Drugs and the lungs. In: Albert RK, Spiro SG, Jett JR, eds. Clinical Respiratory Medicine. 3rd ed. Philadelphia: Elsevier; 2008
102. Ramanathan RK, Reddy W, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996;110:289-292
103. Bonomi P, Faber LP, Warren W, et al. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol 1997;24(4 Suppl 12):S12-123-S12-129
104. Dimopoulou I, Efstathiou E, Samakovli A, et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 2004;15:1250-1255
105. Carron PL, Cousin L, Caps T, et al. Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med 2001;27:1554
106. Vansteenkiste JF, Bomans P, Verbeken EK, et al. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 2001;31:83-85
107. Forsythe B, Faulkner K. Clinical experience with gefitinib (Iressa,ZD1839): an overview of safety and tolerability. Lung Cancer 2003;41(Suppl 2):S70-S71
108. Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer 1999;26:109-112
109. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139
110. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
111. Tassinari D, Sartori S, Gianni L, et al. Is acute dyspnoea a rare side effect of vinorelbine? Ann Oncol 1997;8:503-504
112. Verweij J, van Zanten T, Souren T, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987;60:756-761
113. Rivera MP, Kris MG, Gralla RJ, White DA. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol 1995;18:245-250
114. Raderer M, Kornek G, Hejna M, et al. Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol 1996;7:973-975
115. Chang AYC, Kuebler JP, Pandya KJ, et al. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer 1986;57:2285-2290
116. Torra R, Poch E, Torras A, et al. Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy. Chemotherapy 1993;39:453-456
117. Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR. A prospective srudy of pulmonary function in patients receiving mitomycin. Chest 1996;109:939-944
118. Soares M, Darmon M, Salluh JIF, et al. Prognosis of lung cancer patients with life - threatening complications. Chest 2007;131:840-846
119. http://www.who.int/cancer/palliative/en/ WHO guidelines: Cancer pain relief. 2nd ed. Geneva: World Health Organisation; 1996
120. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995;22(2, Suppl 3):67-72
121. McCaffrey M, Beebe A. Pain: Clinical Manual for Nursing Practice. St. Louis: CV Mosby; 1989
122. Corner J. Innovative approaches in symptom management. Eur J Cancer Care (Engl) 1995;4:145-146
123. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 2000;19:137-153
124. O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care (Engl) 1999;8:37-43
125. Smith EL, Hann DM, Ahles TA, et al. Dyspnea, anxiety, body consciousness and quality of life in patients with lung cancer. J Pain Symptom Manage 2001;21:323-329
126. Muers MF. Opioids for dyspnoea. Thorax 2002;57:922-923
127. Lai YL, Chan CW, Lopez V. Perceptions of dyspnea and helpful interventions during the advanced stage of lung cancer: Chinese patients' perspectives. Cancer Nurs 2007;30:E1-E8
128. Hately J, Laurence V, Scott A, Baker R, Thomas P. Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer. Palliat Med 2003;17:410-417
129. Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996;10:299-305
130. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007;21:177-191; Epub 2007 Mar 15
131. Levin DN, Cleeland CS, Dar R. Public attitudes toward cancer pain. Cancer 1985;56:2337-2339
132. Hoffman AJ, Given BA, von Eye A, Gift AG, Given CW. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. Oncol Nurs Forum 2007;34:785-792
133. World Health Organization. WHO's Pain Relief Ladder. http://www.who.int/ cancer/palliative/painladder/en/index.html. Accessed April 1, 2008
134. Larue F, Colleau SM, Brasseur L, et al. Multicentre study of cancer pain and its treatment in France. BMJ 1995;310:1034-1037
135. Brown J, Thorpe H, Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005;23(30):7417-7427
136. Lin HR, Bauer-Wu SM. Psycho-spiritual well-being in patients with advanced cancer: an integrative review of the literature. J Adv Nurs 2003;44:69-80
137. Sand L, Strang P. Existential loneliness in a palliative home care setting. J Palliat Med 2006;9:1376-1387
138. Osse BHP, Vernooij-Dassen MJFJ, Schade E, Grol RPTM. The problems experienced by patients with cancer and their needs for palliative care. Support Care Cancer 2005;13:722-732
139. Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E. The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manage 2007;34:370-379